Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...

Hello and welcome to the Geron fourth quarter and full year 2024 earnings call. All lines have been placed on mute to prevent ...

FOSTER CITY, Calif. (AP) — FOSTER CITY, Calif. (AP) — Geron Corp. (GERN) on Wednesday reported a loss of $25.4 million in its fourth quarter. The Foster City, California-based company said it had a ...

Geron ended 2024 with a strong cash position and reported that revenues for the third and fourth quarters exceeded expectations. The company’s net product revenue for RYTELO reached $47.5 million in ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to p ...

B. Riley dropped their FY2025 earnings per share (EPS) estimates for shares of Geron in a research report issued to clients ...

B. Riley decreased their FY2027 earnings estimates for shares of Geron in a research note issued to investors on Tuesday, ...

GERN's Rytelo, approved in mid-2024, shows promising initial sales, with Q3'24 net revenues at $28.2M, and preliminary Q4'24 net revenues of $45M-$46M. Despite some market exclusivity concerns ...